Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
| ▸ | BRD2 | P25440 | 2/20 | 0.30 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397533 | 0.89 | SLC2A1 (0.42) | SLC2A1DGAT1BRD4BRD2BRD3 | |
| SCHEMBL13754686 | 0.81 | SLC2A1 (0.56) | SLC2A1BRD4CREBBP | |
| SCHEMBL4469233 | 0.79 | SLC2A1 (0.52) | SLC2A1BRD4CREBBPPTGES | |
| SCHEMBL4484452 | 0.78 | SLC2A1 (0.53) | SLC2A1PTGES | |
| SCHEMBL4476932 | 0.78 | GPR84 (0.48) | SLC2A1DGAT1 | |
| SCHEMBL4490726 | 0.77 | SLC2A1 (0.61) | SLC2A1DGAT1PTGES | |
| SCHEMBL4487955 | 0.76 | SLC2A1 (0.66) | SLC2A1DGAT1PTGES | |
| SCHEMBL4493447 | 0.75 | SLC2A1 (0.52) | SLC2A1DGAT1PTGES | |
| SCHEMBL4476493 | 0.75 | SLC2A1 (0.52) | SLC2A1PTGES | |
| SCHEMBL3425836 | 0.74 | CYP11B1 (0.37) | SLC2A1DGAT1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246329-A1 | 4(1H)-pyridinone derivatives and their use as antimalaria agents | Glaxo Group Limited (GB) | 2010-11-03 | — | — | EP | disclosed |
| EP-2246329-A1 | 4(1H)-pyridinone derivatives and their use as antimalaria agents | Glaxo Group Limited (GB) | 2010-11-03 | — | — | EP | disclosed |